You have no items in your cart.
Describe the syndication and licensing services provided by BioNews Services.
The syndication and licensing service is a division of BioNews Services, LLC, a leading online health, science, and research publication company that covers a broad spectrum of issues affecting patients living with rare diseases. The vast amount of daily content produced by BNS journalists, research scientists, and patient columnists is made available to newspapers, news/feature services, magazines, medical journals, and other health and well-being publications under licensing contracts with BNS.
How is the content used?
Under BNS licensing agreements, contracted entities are able to publish BNS content across multiple digital and print platforms to serve the interests of large segments of their target audiences and drive advertising and other revenue streams. The service produces dozens of daily stories, patient columns, photos, and other content. And access to the vast archives of BNS content is included in full-service licensing agreements.
Are BNS clients restricted in how they can use the content?
Licensing agreements allow clients to use BioNews content across all contractually specified media platforms. Repurposing, selling, or bartering the content for any use beyond the client’s specified platforms, websites, print publications, and other products is not allowed.
What rare diseases do you cover?
A team of seasoned journalists, PhD research scientists, and patient columnists provide compelling, essential multi-tiered coverage of more than 60 diseases.
Staff reporters and editors produce stories covering drug trials and approvals; research findings; issues affecting caregivers; treatment developments; FDA actions; social and cultural trends related to coping with rare diseases; and legislative issues that affect patient well-being, such as FDA decisions.
What types of content are provided?
BNS uses all its resources to provide multidimensional coverage — news stories, analyses, columns, Q&As, in-depth interviews with leading researchers, and resource materials to empower readers with information they can act on.
And, in addition to the extensive daily coverage, the service produces quarterly special report content modules dedicated to covering high-profile topics in the news in depth and with unrivaled quality and effectiveness. These quarterly reports are designed to not only reach broad audiences, but to generate incremental advertising revenue.
Can specific stories, columns, or other content be licensed separately?
Yes. BNS offers yearly agreements that enable outside media to make “one-off” purchases of content within specified guidelines and procedures.
What quality control measures are in place?
All BNS content is reported, fact-checked, and edited under the strictest protocols for quality, accuracy, and sourcing in all content. The editorial operations within BNS function entirely independent from any outside influences and under the highest ethical reporting standards.
What licensing options exist?
There are three types of licensing arrangements:
1) Full Access. Yearly contractual agreements that grant full use of all content, including BNS archives.
2) Special Reports: Yearly contractual agreements for use of quarterly special reports dedicated to a specific, high-profile topic. Each quarter, the service produces a multi-layered content module dedicated to a major rare disease topic, such as COVID-19.
3) Limited Access. Organizations interested in access to specific types of content — coverage of a single disease, use of a regular column, etc. — can contract for modified use of the content on a yearly basis. These agreements are tailored to meet specific market and advertising needs.
How are the topics for quarterly special reports chosen?
Special reports are designed to explore a compelling issue, major news event, or rare disease trend in depth. Senior editors choose the themes based on measured interest in the topic (SEO, readership, social media activity, etc.), appeal to broad audiences, potential to drive revenue, and overall newsworthiness.
These reports include multiple stories, columns, Q&As, graphics or illustrations, photos, video segments, and layers of resource information. They provide the ingredients for building website portals or other digital platforms, as well as print special sections or multi-part series, to drive incremental advertising and build readership.
What are some examples of themed special reports?
The global spread of COVID-19 is one of the most significant stories of the past century. Our COVID-19 module produces scores of stories, columns, interactive features, and news alerts to provide in-depth coverage of how the coronavirus affects rare disease patients, their healthcare providers, and family members.
Other examples of single-topic special reports include: cannabis and rare diseases, major drug approvals, the critical role of community support groups, global Rare Disease Day, treatment trends, medical conferences, etc.
Does BNS maintain a troubleshooting service desk?
Syndicated content from BNS is managed by a team of experienced editors who oversee and update daily news digests, building and maintaining a relationship with the service’s clients to ensure expectations are met and any issues or concerns are addressed promptly.
Where is BNS located?
BNS’s main office is based in Pensacola, Florida. However, the vast majority of staff work from remote locations, where the science is generated and where the expertise in covering rare diseases is most prevalent. In addition to locations across the United States, BNS has researchers, editors, columnists, and reporters in Portugal, France, Israel, Turkey, and several other countries.